ライフサイエンスコーパス: osteoporosis

1 which have features of accelerated aging and osteoporosis.

2 one-targeting rAAV-mediated gene therapy for osteoporosis.

3 may be more efficacious in the treatment of osteoporosis.

4 ormation and is used in patients with severe osteoporosis.

5 n to prevent bone loss in multiple models of osteoporosis.

6 ting hormone concentration of >=40 U/L) with osteoporosis.

7 e development of odanacatib for treatment of osteoporosis.

8 d thus do not meet the clinical criteria for osteoporosis.

9 for developing bone anabolic agents against osteoporosis.

10 low bone mineral density who are at risk for osteoporosis.

11 ighting a new biological pathway relevant to osteoporosis.

12 e fracture risk in postmenopausal women with osteoporosis.

13 ng injuries and substance abuse, cancer, and osteoporosis.

14 t RANKL, denosumab improves bone strength in osteoporosis.

15 asts in a mouse model of ovariectomy-induced osteoporosis.

16 estoring skeletal integrity in patients with osteoporosis.

17 evices and to human health in the context of osteoporosis.

18 peutic targets for bariatric surgery-induced osteoporosis.

19 , but it is not clear if PPIs directly cause osteoporosis.

20 therapies reduce fracture risk in women with osteoporosis.

21 fically stroke, in postmenopausal women with osteoporosis.

22 antisclerostin antibodies as a treatment for osteoporosis.

23 ps or blocking mAbs in bone diseases such as osteoporosis.

24 gy, intrathoracic and extrathoracic fat, and osteoporosis.

25 L-27 toward the treatment of post-menopausal osteoporosis.

26 ome inhibitors in treating radiation-induced osteoporosis.

27 notypes including amyloidosis, alopecia, and osteoporosis.

28 ill receive these agents to prevent or treat osteoporosis.

29 udes men and women with low bone density and osteoporosis.

30 pha attenuated bone loss in a mouse model of osteoporosis.

31 as well as with metabolic diseases, such as osteoporosis.

32 ties for simultaneously treating obesity and osteoporosis.

33 strated to be involved in the development of osteoporosis.

34 levels/allelic variations and patients with osteoporosis.

35 mice from ovariectomy-induced (OVX-induced) osteoporosis.

36 ammatory disorders such as periodontitis and osteoporosis.

37 er development for potential therapeutics in osteoporosis.

38 PTH, PTH(1-34), is used clinically to treat osteoporosis.

39 for the treatment of bone disorders such as osteoporosis.

40 but also trabecular bone loss, a feature of osteoporosis.

41 reatment of low bone mass disorders, such as osteoporosis.

42 r the treatment of postmenopausal women with osteoporosis.

43 of skeletal diseases, such as osteopenia and osteoporosis.

44 acture in men who have clinically recognized osteoporosis.

45 herapeutic agent for focal radiation-induced osteoporosis.

46 ion, or whether it is a symptom/biomarker of osteoporosis.

47 rstand, diagnose and inform the treatment of osteoporosis.

48 o therapy, or to indicate possible secondary osteoporosis.

49 vertebral fractures in women who have known osteoporosis.

50 potential therapeutic target for age-related osteoporosis.

51 used in the treatment of bone malignancy or osteoporosis.

52 fic treatment option for WNT1-related OI and osteoporosis.

53 umor metastasis, renal tubular acidosis, and osteoporosis.

54 approved for the treatment of postmenopausal osteoporosis.

55 n the pathogenesis of glucocorticoid-induced osteoporosis.

56 diabetes, cataracts, glaucoma, or osteopenia/osteoporosis.

57 been applied to dissect the pathogenesis of osteoporosis.

58 increased risk of fracture are predictors of osteoporosis.

59 the link between muscle aging/senescence and osteoporosis.

60 contribute to bone-related diseases such as osteoporosis.

61 d for intervention of bone disorders such as osteoporosis.

62 isions regarding pharmacologic treatment for osteoporosis.

63 g properties, including for those at risk of osteoporosis.

64 ogies individually to identify mechanisms of osteoporosis.

65 such as kidney disease, stomach cancer, and osteoporosis.

66 druggable regulators of bone homeostasis and osteoporosis.

67 y and type 2 diabetes but is associated with osteoporosis.

68 sing ovariectomized (OVX) mice as a model of osteoporosis.

69 ess activity can contribute to bone loss and osteoporosis(10).

70 joint replacement (6.02, 95% CI 4.66-7.77), osteoporosis (2.69, 95% CI 1.35-5.38), and anxiety (2.00

71 In women with osteoporosis, 4 years of alendronate reduced clinical fr

72 In women with osteopenia or osteoporosis, 6 years of zoledronic acid reduced clinica

73 Osteoporosis, a condition of skeletal decline that under

74 bilitating side effects, e.g., skin atrophy, osteoporosis, Addison-like adrenal insufficiency, fatty

75 s study was to determine the extent to which osteoporosis affects the jaw skeleton and then to evalua

76 We investigated the induction of osteoporosis after 8 months using 31 female merino land

77 11 community-dwelling healthy adults without osteoporosis, aged 55 to 70 years, with baseline levels

78 Collectively, this study demonstrates that osteoporosis aggravates OA symptoms.

79 sity, and evaluation for secondary causes of osteoporosis) agreed with existing guidance for individu

80 hundred and three had decreased BMD (61 with osteoporosis and 42 with osteopenia) and 70 were healthy

81 We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assig

82 ey syndrome (HCS), a disease presenting with osteoporosis and acro-osteolysis.

83 suppressive treatment, including infections, osteoporosis and cardiovascular and reproductive effects

84 metabolite balance and completely prevented osteoporosis and changes in body composition that charac

85 metabolic and age-related disorders such as osteoporosis and diabetes mellitus.

86 lcitonin receptor (CTR) is a drug target for osteoporosis and diabetes.

87 rnover markers are not used for diagnosis of osteoporosis and do not improve prediction of bone loss

88 However, management of osteoporosis and fracture prevention strategies are ofte

89 s before adulthood could potentially prevent osteoporosis and fractures due to the lifelong effect on

90 neral density (BMD) may be at higher risk of osteoporosis and fractures in later life than their unin

91 neral density (BMD) may be at higher risk of osteoporosis and fractures in later life than their unin

92 ome, an untreatable disease characterized by osteoporosis and fractures, craniofacial developmental a

93 effort to find new and safer treatments for osteoporosis and frailty, we describe a novel series of

94 ium homeostasis and a therapeutic target for osteoporosis and hypoparathyroidism.

95 s the formation of calciprotein particles in osteoporosis and impaired calcium metabolisms.

96 f estrogens at menopause is a major cause of osteoporosis and increased fracture risk.

97 opmental abnormalities, acro-osteolysis, and osteoporosis and is associated with gain-of-NOTCH2 funct

98 es, which affect immunity, inflammation, and osteoporosis and may impair lung function.

99 ovariectomized rats as a model of menopause-osteoporosis and menopause women.

100 romising drug complexes for the treatment of osteoporosis and metastasis.

101 h can be used as a drug for the treatment of osteoporosis and metastasis.

102 strategies to treat chronic diseases such as osteoporosis and obesity.

103 on-pharmacological method of regulating both osteoporosis and obesity.

104 e is the primary co-morbidity of hemophilia, osteoporosis and osteopenia are also observed.

105 Notably, bone mineral density, osteoporosis and osteoporotic fracture are highly herita

106 epsin Z mRNA has strong diagnostic value for osteoporosis and osteoporotic fracture.

107 ctive enriched milk powder in ovariectomized-osteoporosis and ovariectomized rats as a model of menop

108 a paradigm shift in the ability to diagnose osteoporosis and predict individuals who are at risk of

109 idely prescribed pharmacologic treatment for osteoporosis and reduce fracture risk in postmenopausal

110 assessment methods and medications targeting osteoporosis and related fractures, screening for fractu

111 altering PTH expression in diseases such as osteoporosis and secondary hyperparathyroidism.

112 tebral fractures (VFs) aids in management of osteoporosis and targeting of fracture prevention therap

113 rial fibrillation, obstructive sleep apnoea, osteoporosis and venous thromboembolism.

114 ith Hajdu-Cheney syndrome (HCS) present with osteoporosis, and HCS is associated with NOTCH2 mutation

115 responsible for skeletal hypomineralization, osteoporosis, and multiple fractures of long bones, whic

116 with higher risk of cardiovascular disease, osteoporosis, and other conditions.

117 y, our data suggest that WNT1-related OI and osteoporosis are caused in part by decreased mTORC1-depe

118 veolar proteinosis, autoimmune disorders and osteoporosis, are limited.

119 Osteoporosis arises from imbalanced activity of osteocla

120 l fractures adjudicated as being a result of osteoporosis as assessed by clinical history and radiogr

121 (SHN3) is a promising therapeutic target for osteoporosis, as deletion of shn3 prevents bone loss in

122 er inflammation is etiologically relevant to osteoporosis, assessed from bone mineral density (BMD),

123 bone mass, 6-month-old mutant mice developed osteoporosis, associated with an increase in osteoclasto

124 At baseline, 27% of patients had osteoporosis, associated with the length of hospitalizat

125 The prevalence of osteoporosis at baseline at the lumbar spine (LS) and fe

126 l-Ab) indicated in postmenopausal women with osteoporosis at high risk for fracture.

127 f diabetes, cardiovascular disease, obesity, osteoporosis, atlantoaxial instability, thyroid disease,

128 Fractures resulting from osteoporosis become increasingly common in women after a

129 In people with osteoporosis, bone turnover markers might be useful to a

130 ests a novel treatment strategy not only for osteoporosis, but also for multiple age-related comorbid

131 een shown to reduce fractures in adults with osteoporosis, but has not been formally studied in HIV-i

132 een shown to reduce fractures in adults with osteoporosis, but has not been formally studied in youth

133 during aging could treat/prevent age-related osteoporosis by inhibiting bone destruction and promotin

134 Inflammaging induces osteoporosis by promoting bone destruction and inhibitin

135 for serious infection, respiratory disease, osteoporosis, cardiovascular disease, cancer, and mortal

136 act infection, osteomyelitis, cholecystitis, osteoporosis, cauda equina syndrome, and osseous defect)

137 years +/- 13.8) were recruited from a single osteoporosis center.

138 imaging biomarkers at chest CT, such as for osteoporosis, chronic obstructive pulmonary disease, int

139 or chronic conditions such as heart disease, osteoporosis, cognitive impairment, or some types of can

140 Patients with osteoporosis defined by a clinical event, namely a fragi

141 and long-term deficiency has been linked to osteoporosis, diabetes and cancer.

142 r the treatment of chronic diseases, such as osteoporosis, diabetes and obesity.

143 We note a watershed in osteoporosis drug discovery around the year 2000, when t

144 Optimal long-term osteoporosis drug treatment (ODT) is uncertain.

145 Yet, osteoporosis drugs that not only inhibit bone resorption

146 Nevertheless, osteoporosis drugs that target only osteoclast activity

147 No clinical trials have compared osteoporosis drugs with incident fractures as the primar

148 th TRAF3 deleted in MPCs develop early onset osteoporosis due to reduced bone formation and enhanced

149 ap to illuminate the complex pathogenesis of osteoporosis, especially from molecular functional aspec

150 odifiable risk factor for bone fractures and osteoporosis, especially in low-income communities.

151 py, the reversibility of most treatments for osteoporosis, except for the bisphosphonates, has dampen

152 A state-transition microsimulation model of osteoporosis for postmenopausal women aged 55 years or o

153 disability weights proposed by the National Osteoporosis Foundation and did a series of sensitivity

154 According to the U.S. National Osteoporosis Foundation guidelines, postmenopausal women

155 events (IRR, 2.43 [95% CI, 1.11-5.33]), and osteoporosis/fracture (IRR, 1.43 [95% CI, 1.03-2.01]).

156 mpairment, chronic kidney disease [CKD], and osteoporosis/fracture [OF]).

157 with an increased risk of kidney disease and osteoporosis/fracture, this risk did not seem to be depe

158 events, 41 and 14 kidney events, 230 and 121 osteoporosis/fractures, 82 and 94 diabetes mellitus, 114

159 d in 5 validation cohorts using the National Osteoporosis Guideline Group clinical guidelines (N = 10

160 three decades, the mainstay of treatment for osteoporosis has been antiresorptive agents (such as bis

161 Impairment of osteoblast function and osteoporosis has been described in patients receiving VK

162 approach therefore aids target discovery in osteoporosis, here on the example of two relevant genes

163 rs are targets for existing drugs that treat osteoporosis, hypercalcaemia, Paget's disease, type II d

164 d with significantly greater odds of AEs for osteoporosis, hypertension, obesity, type 2 diabetes, ga

165 ales, the main manifestations of SRS include osteoporosis, hypotonic stature, seizures, cognitive imp

166 osteogenesis imperfecta (OI) and early-onset osteoporosis, identifying it as a key Wnt ligand in huma

167 Prevention of osteoporosis in adulthood begins with optimizing bone he

168 cathepsin Z mRNA levels are associated with osteoporosis in clinical samples.

169 are associated with decreased bone mass and osteoporosis in humans.

170 KL/OPG ratio showed that the steroid-induced osteoporosis in its late progressive phase stimulates RA

171 s pool, and impaired osteogenesis as well as osteoporosis in later life.

172 drug therapy available for the treatment of osteoporosis in males and postmenopausal females.

173 ral density (BMD), or preventing or delaying osteoporosis in men with nonmetastatic prostate cancer.

174 bsequent bone density measurement identified osteoporosis in one proband.

175 Consistent with the common finding of osteoporosis in patients, we found reduced bone depositi

176 A) is cost-effective as a screening tool for osteoporosis in postmenopausal women.

177 evidence-based guidance on the management of osteoporosis in survivors of adult cancer.

178 erlying genomic and molecular mechanisms, of osteoporosis in vivo in humans is still challenging.

179 ow that mice deficient in SMURF2 have severe osteoporosis in vivo.

180 n therapy or raloxifene for the treatment of osteoporosis in women.

181 he 5-year pharmacologic treatment period for osteoporosis in women.

182 rogenic complication, glucocorticoid-induced osteoporosis, in a substantial proportion of patients.

183 Z could be a future diagnostic biomarker for osteoporosis including female osteoporosis patients over

184 s indicated, bisphosphonates or denosumab at osteoporosis-indicated dosages are the preferred interve

185 Osteoporosis induction in a sheep model by steroid admin

186 RANKL/OPG ratio correlation to the method of osteoporosis induction.

187 Osteoporosis is a chronic condition and long-term, somet

188 Osteoporosis is a common age-related disorder leading to

189 Osteoporosis is a common aging-related disease diagnosed

190 Osteoporosis is a common and debilitating bone disease t

191 Osteoporosis is a common disease diagnosed primarily by

192 Osteoporosis is a common systemic skeletal disorder resu

193 Osteoporosis is a complex disease with a strong genetic

194 Osteoporosis is a condition characterized by low bone mi

195 Osteoporosis is a devastating disease with an essential

196 Osteoporosis is a highly prevalent disorder characterize

197 Osteoporosis is a major health problem, making bones fra

198 Osteoporosis is a metabolic bone disorder associated wit

199 Background Osteoporosis is a prevalent, under-diagnosed, and treata

200 Osteoporosis is an enormous and growing public health pr

201 Osteoporosis is associated with decreased bone density a

202 Osteoporosis is associated with increased fragility of b

203 Osteoporosis is caused by increased bone resorption and

204 Osteoporosis is characterised by trabecular bone loss re

205 Age-related osteoporosis is characterized by the deterioration in bo

206 Osteoporosis is currently treated with drugs targeting t

207 The diagnosis of osteoporosis is intimately linked with the imaging and q

208 Osteoporosis is predominantly treated with drugs that in

209 etary acid load (DAL) in the pathogenesis of osteoporosis is still debated.

210 Glucocorticoid-induced secondary osteoporosis is the most predictable side effect of this

211 k of experiencing any fracture or initiating osteoporosis medication (HR: 0.84; 95% CI: 0.76 to 0.93)

212 re included only if they had no prior use of osteoporosis medication and they had undergone 180 days

213 Use of osteoporosis medication was higher at the end of year 1

214 orotic fracture, any fracture, initiation of osteoporosis medication, and a combined endpoint.

215 ad at least 6 months of follow-up; evaluated osteoporosis medications among patients with CKD; and re

216 Effects of osteoporosis medications on BMD, fracture risk, and safe

217 Osteoporosis medications that inhibit osteoclasts have b

218 d raloxifene are among the most popular anti-osteoporosis medications.

219 in a number of endocrine diseases, including osteoporosis, metabolic syndrome and type 2 diabetes mel

220 Administration of 24 in a rat osteoporosis model demonstrates its bone-sparing efficac

221 rats were used as a menopause and menopause-osteoporosis model, respectively.

222 ays, we generated a medaka (Oryzias latipes) osteoporosis model, where inducible expression of recept

223 pharmacokinetic profile for testing in a rat osteoporosis model.

224 ovariectomized and dexamethasone treated rat osteoporosis model.

225 odeling and angiogenesis in a postmenopausal osteoporosis mouse model.

226 igh blood pressure (HBP), diabetes mellitus, osteoporosis, non-AIDS cancer, chronic renal failure, ca

227 s of high blood pressure, diabetes mellitus, osteoporosis, non-AIDS cancer, chronic renal failure, ca

228 One patient was diagnosed with transient osteoporosis of the hip and one with a stress fracture o

229 which causes neurodevelopmental defects and osteoporosis, often leading to extremely fragile bones.

230 Osteoporosis, one of the most prevalent chronic ageing-r

231 Imbalance will lead to conditions such as osteoporosis or hyperostosis.

232 ity fracture on therapy, secondary causes of osteoporosis or non-compliance with medical therapy shou

233 Osteoporosis or osteopenia are common clinical manifesta

234 rpose of this study was to determine whether osteoporosis or osteopenia is associated with periodonta

235 s were associated with a lower likelihood of osteoporosis (OR from 0.54 to 0.75).

236 neral density analysis, three presented with osteoporosis/osteopenia.

237 th PTx; while nephrolithiasis (P = 0.07) and osteoporosis (P = 0.34) did not affect the PTx rate.

238 BMD (P-value = 2.1 x 10(-18)), and increased osteoporosis (P-value = 4.2 x 10(-5)) and fracture risk

239 NPs to causal genes, offers new insight into osteoporosis pathophysiology, and highlights opportuniti

240 ng non-osteoporotic controls, osteopenia and osteoporosis patients (p < 0.0001) and in female osteopo

241 cantly associated with fragility fracture in osteoporosis patients (P = 0.0018).

242 oporosis patients (p < 0.0001) and in female osteoporosis patients over the age of 50 years (P = 0.00

243 biomarker for osteoporosis including female osteoporosis patients over the age of 50 years.

244 na13 conditional knockout mice have a severe osteoporosis phenotype.

245 Postmenopausal osteoporosis (PMO) is a risk factor for periodontitis, a

246 l during childhood is a critical step toward osteoporosis prevention.

247 Ovariectomized and ovariectomized-osteoporosis rats were used as a menopause and menopause

248 No correlation was found between FMD and osteoporosis, recurrent anaphylaxis, presence of skin le

249 d in 31 of 80 participants, the fracture was osteoporosis related.

250 hazard ratio, 2.1; 95% CI: 1.1, 4.2) and any osteoporosis-related fracture (hazard ratio, 4.0; 95% CI

251 e interval [CI]: 1.4, 4.7; P = .002) and any osteoporosis-related fracture (hazard ratio, 8.1; 95% CI

252 (i) long-term PM <2.5 mum (PM2.5) levels and osteoporosis-related fracture hospital admissions among

253 were any incident fracture and any incident osteoporosis-related fracture registered in the National

254 duce the primary outcome of incidence of all osteoporosis-related fractures (hazard ratio [HR] 0.94,

255 roportion of individuals who had one or more osteoporosis-related fractures over a 5-year period.

256 nalysis, risk of bone fracture admissions at osteoporosis-related sites was greater in areas with hig

257 rlying mechanisms for laminopathy-associated osteoporosis remain largely unclear.

258 is; however, its role in the pathogenesis of osteoporosis remains to be determined.

259 oestrogen deficiency, a cardinal feature of osteoporosis, remains unknown.

260 Osteoporosis represents a major health problem, resultin

261 Osteoporosis results from the imbalance between bone res

262 re, we demonstrate significant enrichment of osteoporosis risk variants among high-confidence osteocl

263 ify a number of potential effector genes for osteoporosis risk variants, which will help focus functi

264 ral density is a cost-effective strategy for osteoporosis screening in postmenopausal women and has t

265 oracic CT provide a valuable opportunity for osteoporosis screening regardless of the clinical indica

266 s and could potentially enable opportunistic osteoporosis screening.

267 Patients who are treated for osteoporosis should be monitored regularly to track expe

268 In women with unspecified osteoporosis status, 5 to 7 years of hormone therapy red

269 s (n = 865-896) from the Boston Puerto Rican Osteoporosis Study (BPROS) with complete bone and dietar

270 = 6,004), and replicated in the Kansas City Osteoporosis Study (KCOS, N = 2,207).

271 uerto Ricans, a population at higher risk of osteoporosis than previously appreciated.

272 ne (PTH), is the only approved treatment for osteoporosis that increases the rate of bone formation.

273 on is susceptible to the untoward effects of osteoporosis that manifest as thinner, more porous alveo

274 his Review, we summarize the epidemiology of osteoporosis, the history of scanning modalities, fractu

275 ION: Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fra

276 in relation to other therapeutic options for osteoporosis to better guide their clinical application

277 dations on treatment of low bone density and osteoporosis to prevent fractures in men and women.

278 current study reproduced the sheep model of osteoporosis to study the RANKL/OPG ratio correlation to

279 Long-term safety and efficacy of osteoporosis treatment are important because of the chro

280 hey were unable or unwilling to use approved osteoporosis treatment.

281 might be a potential therapeutic target for osteoporosis treatment.

282 ne mineralization impairment before specific osteoporosis treatment.

283 Exposure to BPs and the use of other osteoporosis treatments during follow-up were determined

284 High frequencies of densitometric osteoporosis, vitamin D deficiency, bone markers abnorma

285 use, likely prescribed for the management of osteoporosis, was not associated with decreased breast c

286 To identify genes with a role in osteoporosis, we integrate the eBMD GWAS association res

287 , postmenopausal women aged 60-90 years with osteoporosis were enrolled in 214 centres in North Ameri

288 and their individual components with BMD and osteoporosis were tested with ANCOVA and logistic regres

289 isphosphonates are the frontline therapy for osteoporosis, which act by reducing bone remodelling, an

290 Bone diseases, such as osteoporosis, which are characterized by high rates of b

291 o future treatments for arteriosclerosis and osteoporosis, which are strongly associated with ageing

292 , we trace the evolution of drug therapy for osteoporosis, which began in the 1940s with the demonstr

293 ed estrogen deficiency increases the risk of osteoporosis, which can be effectively treated with the

294 affinity show potential to prevent and treat osteoporosis while minimizing or eliminating carcinogeni

295 ed >/=55 to </=90 years) with postmenopausal osteoporosis who had taken an oral bisphosphonate for at

296 In postmenopausal women with osteoporosis who were at high risk for fracture, romosoz

297 al bone loss during rheumatoid arthritis and osteoporosis, whose pathogenesis is associated with a Th

298 ddition to implications for the treatment of osteoporosis with PTH analogs, this pathway may be part

299 juvenating MSCs and ameliorating age-related osteoporosis, with a promising therapeutic potential in

300 e biopsy from a male patient with idiopathic osteoporosis (without indication of renal impairment), w